Felbinac
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Felbinac
- Felbinac: From Topical Anti-inflammatory Use to Brachyolmia-Amelogenesis Imperfecta Syndrome
Felbinac: From Topical Anti-inflammatory Use to Brachyolmia-Amelogenesis Imperfecta Syndrome
One-Sentence Summary
Felbinac (DrugBank DB07477) has no confirmed original indication on record in this evidence pack, but is described in the underlying data as a topical NSAID (COX inhibition, local anti-inflammatory/analgesic action). The TxGNN model’s top prediction is Brachyolmia-Amelogenesis Imperfecta Syndrome, a rare genetic skeletal/dental dysplasia, but this pairing has zero clinical trials, zero literature, and no known mechanistic link — the model’s own rationale text flags a lack of biological plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record (no approved indication text available; drug reportedly classified as a topical NSAID) |
| Predicted New Indication | Brachyolmia-amelogenesis imperfecta syndrome |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the information embedded in the model’s own rationale text across candidates, Felbinac is a topical NSAID acting through COX inhibition to produce local anti-inflammatory and analgesic effects.
Brachyolmia-amelogenesis imperfecta syndrome, however, is a hereditary skeletal and dental developmental disorder caused by structural genetic defects — it is not an inflammatory condition. The evidence pack’s own mechanistic_link assessment for this top-ranked candidate explicitly states there is no known mechanistic relationship between COX-mediated anti-inflammatory action and this genetic syndrome, and that the model’s high confidence score “lacks biological plausibility support.”
Notably, several lower-ranked candidates in this pack (e.g., rank 6 spondyloarthropathy, rank 7 rheumatoid nodulosis, ranks 9–10 juvenile idiopathic arthritis) are inflammatory joint conditions where NSAID pharmacology has directional plausibility — these may be more scientifically defensible follow-up targets than the top-ranked prediction, even though none currently have Felbinac-specific trial or literature support either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Felbinac has no marketing authorizations on record in Taiwan (0 registrations; market status: Not marketed / Not Marketed).
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications for Felbinac are currently a Blocking data gap (DG001) — this must be resolved before any safety-stage (S1) evaluation can proceed, and no drug interaction data could be located (DDI query: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on an L5 model score with no supporting trials or literature, and the pack’s own mechanistic assessment finds no biological plausibility for the top-ranked indication (brachyolmia-amelogenesis imperfecta syndrome). Combined with the blocking gap on TFDA safety labeling and the drug’s unmarketed status in Taiwan, this candidate does not meet the bar to advance.
To proceed, the following is needed:
- TFDA package insert data (warnings/contraindications) to close the blocking gap (DG001)
- Confirmed mechanism of action via DrugBank API (DG002)
- If pursuing repurposing, redirect evaluation toward mechanistically plausible candidates lower in the ranking (e.g., spondyloarthropathy, JIA) and search for Felbinac-specific evidence there
- Dedicated literature/trial search for Felbinac in inflammatory joint disease before any further staging
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.